Vaccine Platforms & Antimicrobials
Maturity
capability 4 / 5
deployment 3 / 5 ← sets the score
absorption 3 / 5 ← sets the score
Bound by incentives · trend deteriorating.
Basis, source, vintage
Vaccine platforms are demonstrably mature; the antimicrobial half is a market failure with a thin pipeline. The score is the blend and the halves must be written separately.
Source: WHO, Antibacterial agents in clinical and preclinical development, 14 Jun 2024 (cutoff 31 Dec 2023): 97 products in clinical development, only 3 in pre-registration. Post-approval insolvencies: Achaogen Ch.11 Apr 2019 (Zemdri approved Jun 2018, ~$800k revenue by end-2018, assets sold $16m against ~$300m development cost), Aradigm Feb 2019, Melinta Dec 2019 (2023–2024)
What it is
Rapid-response vaccine technologies and the development of new classes of antibiotic and antimicrobial agent.
What it does
It is the enabler standing between a pathogen and a pandemic, and between antimicrobial resistance and a return to pre-antibiotic medicine. Its two halves are moving in opposite directions.
Common misconception
That vaccine platform success implies antimicrobial success. Vaccines had a demonstrated pandemic response; the antibiotic pipeline is nearly empty, and for market reasons rather than scientific ones.
Steepens
- Zoonotic and Antimicrobial Resistance Risk — large
- Food System Transformation — moderate
- Longevity and the Healthspan Gap — moderate
What would change its gradient
- Pull incentives — subscription or market-entry rewards that decouple revenue from volume
- Stewardship, which reduces resistance pressure and cuts revenue further
- Surveillance capacity, which determines how early anything is seen
Shares megatrends with
- BioTech & Genomics
- Gene Editing
- Synthetic Biology
- AgTech
- Alternative Proteins & Precision Fermentation
- Assistive & Care Technology
In the book
Why the Future Arrives Unevenly — Ch. 9 — The Closing of the Planetary Envelope · Ch. 12 — Reading the Ramp
Sources
- Vaccine platforms are demonstrably mature; the antimicrobial half is a market failure with a thin pipeline. The score is the blend and the halves must be written separately. Source: WHO, Antibacterial agents in clinical and preclinical development, 14 Jun 2024 (cutoff 31 Dec 2023): 97 products in clinical development, only 3 in pre-registration. Post-approval insolvencies: Achaogen Ch.11 Apr 2019 (Zemdri approved Jun 2018, ~$800k revenue by end-2018, assets sold $16m against ~$300m development cost), Aradigm Feb 2019, Melinta Dec 2019 (2023–2024).